Author(s): Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, Schellens JH,
Abstract Share this page
Abstract Atazanavir is the most recently introduced protease inhibitor for the suppression of the anti-human immunodeficiency virus. A sensitive and selective reversed-phase liquid chromatographic assay for this drug in human plasma has been developed and validated. Atazanavir was isolated from a 500 microL plasma sample using liquid-liquid extraction with dichloromethane. After evaporation and reconstitution of the extract the sample was analysed using liquid chromatography and ultraviolet detection at 280 nm. In the evaluated concentration range (44-4395 ng/mL atazanavir), intra-day precisions were < or =7\% and inter-day precisions were < or =14\%. Accuracies between 96 and 106\% were found. The lower limit of quantification was 44 ng/mL with an intra-day precision of 7\%, an inter-day precision of 14\% and an accuracy of 87\%. There was no interference from 32 tested potentially co-administrated drugs and metabolites. The usefulness of the assay was demonstrated for samples obtained from an HIV-infected patient treated with atazanavir. Copyright 2005 John Wiley & Sons, Ltd.
This article was published in Biomed Chromatogr
and referenced in Journal of Chromatography & Separation Techniques